Eris Lifesciences ERIS
Chronic-focused Indian branded formulations (diabetes, cardiac, derma) built through acquisitions, now including insulins and injectables
Mapped in 1 theme: Pharmaceuticals.
Where Eris Lifesciences sits in the supply chain
Eris Lifesciences appears in 1 supply-chain layer in one theme, Pharmaceuticals.
Pharmaceuticals › India branded formulations
OperatorOther companies in this layer
Revenue and profit
| ₹ Cr | FY24 | FY25 | FY26 |
|---|---|---|---|
| Revenue | 2,009 | 2,894 | 3,129 |
| Net profit | 397 | 375 | 648 |
Latest-year revenue ₹3,129 Cr (FY26, company-wide). Wider screens show FY22 onwards.
Strengths
- Almost entirely domestic and chronic-weighted portfolio with high gross margins
- Bought Biocon's Indian branded formulations and insulin brands and Swiss Parenterals - moves it into injectables and insulins
- FY26 profit jumped to ₹648 Cr as acquisitions matured
Risks
- Acquisition-led growth has raised leverage and amortisation
- Insulin and injectables are new manufacturing capabilities
- Semaglutide and SGLT2 generics intensify competition in its core diabetes franchise
Common questions
What does Eris Lifesciences do?
Chronic-focused Indian branded formulations (diabetes, cardiac, derma) built through acquisitions, now including insulins and injectables.
Where does Eris Lifesciences sit in the supply chain?
Eris Lifesciences (NSE: ERIS) is mapped in 1 supply-chain layer: India branded formulations (Pharmaceuticals).
Who are Eris Lifesciences' peers?
In the India branded formulations layer of Pharmaceuticals: Sun Pharmaceutical Industries, Mankind Pharma, Torrent Pharmaceuticals, Alkem Laboratories, Abbott India, Cipla and 4 more.
What is Eris Lifesciences' market cap and valuation?
As of 30 Oct 2026: market cap ₹16,042 Cr, P/E 21.5x, ROCE 14.1%, ROE 18.7%, dividend yield 0.62%.